Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report released on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm decreased their price objective on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a buy rating on the stock in a research note on Monday, September 23rd.

Aptevo Therapeutics Price Performance

APVO opened at $0.18 on Friday. Aptevo Therapeutics has a 52-week low of $0.14 and a 52-week high of $21.56. The business’s fifty day moving average is $0.35 and its 200-day moving average is $1.06.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.26. On average, research analysts expect that Aptevo Therapeutics will post -4.3 earnings per share for the current year.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is currently owned by institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.